Positive topline results of Apnimed's LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...

Amid Q2 chaos, Ithaka outperformed by backing resilient growth stocks like Nvidia and Microsoft. See how they’re navigating ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

As uncertain tariff news continues to dominate Wall Street, Indiana's economy may be impacted. Jane King, a Nasdaq Analyst, ...

Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless.Eli ...

President Donald Trump says he's found a way to achieve his goal of removing Federal Reserve Chair Jerome Powell, accusing ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 4.1% in the morning session after the company ...

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...